hFCRN(2)

The endogenous mouse Fcgrt gene was replaced by human FCGRT gene.While hFCRN(Stock No.NM-HU-00109) and hFCRN(3)(Stock No.NM-HU-2000032）mice function similarly to hFCRN(2) mice,for more detailed information please contact our technical advisor.

Fig1. Validation of hFCGRT and mFCGRT expression in humanized Fcgrt mice by Western blot. These results showed that hFCGRT can be expressed in the liver and kidney of humanized Fcgrt homozygous and heterozygous mice，while mFCGRT can not be expressed in the humanized Fcgrt homozygous mice.

Fig2. Blood concentration curves of Keytruda in C57BL/6 and hFcRn KI mice. (n=3/time point/group)

Fig3. Blood concentration curves of Cyramza(A) and Keytruda(B) in C57BL/6, hFcRn KI and Fcgrt-KO mice.(n=3/time point/group)

Fig4. In vivo PK profiles of TAA scfv-anti HSA VHH in hALB/hFCRN mice(NM-HU-200278) (female, 10-12weeks, n=3 mice/timepoint), which were generated by crossing hFCRN(NM-HU-190070) with hALB(NM-HU-200003). (In cooperation with the third party).

Fig5. Blood concentration curves of test articles in C57BL/6 and hFcRn/hALB dKI mice(NM-HU-200278) , which were generated by crossing hFCRN(NM-HU-190070) with hALB(NM-HU-200003).(In cooperation with the third party)

Fig.6 Pharmacokinetic analysis of IBI112 in HO hFcRn mice. (A) Body weight. (B) Pharmacokinetic analysis parameters. On Day 0, WT C57BL/6 and Hom hFcRn mice were intravenously injected via the tail vein with IBI112 (hIgG1 Fc) and the YTE-modified IBI112 antibody (5 mg/kg), respectively. Blood was drawn at the indicated times, and serum was obtained for pharmacokinetic analysis (n=3 females, 8-10 weeks old). The results showed that, although a prolonged half-life of the YTE-modified IBI112 antibody in Hom hFcRn mice compared to WT C57BL/6 mice, the difference was not statistically significant due to large within-group variation. Data are shown as mean ± SEM.